×

Biotech and Pharmaceuticals Pharmaceuticals

  • Brent Saunders, CEO of Botox maker Allergan PLC, last September announced a new "social contract" under which the company would limit annual list price increases for its drugs to below 10 percent. After deducting the discounts insurers and other payers get off the higher list price, Allergan will receive net price increases of around 2 percent to 3 percent on its...

  • Feb 24- Pfizer Inc said it received subpoenas from the U.S. Attorney's Office for the District of Massachusetts related to its support for organizations that provide financial help to Medicare patients. In a regulatory filing on Thursday, Pfizer said the December 2015 and July 2016 subpoenas were related to groups that help cover patient co-payments for...

  • Cramer: What investors need to watch from Buffett next week

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Cramer's game plan: Key signals to watch from Warren Buffett

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Warren Buffett

    Jim Cramer explains what to listen for from the Oracle of Omaha next week, and key earnings on his radar.

  • Incyte

    Shares of Incyte rose more than 6 percent in Friday trade on news that the pharmaceutical company will join the S&P 500.

  • A heroin user prepares to inject himself in New London, Conn.

    The death rate from drug overdoses more than doubled between 1999 and 2015, according to a report from the CDC.

  • Feb 24- Cempra Inc said on Friday that its oral experimental drug to treat acute bacterial skin infections met the main goal of a late-stage study, sending the company's shares surging about 40 percent in premarket trading. ABSSSI leads to hospitalization of about 5.2 million patients in the United States and Western Europe each year and is often treated with...

  • FRANKFURT, Feb 23- Buyout firm Advent International raised the stakes in a battle for German generic drugs maker Stada Arzneimittel on Thursday with a 3.6 billion euro takeover offer, giving management until Monday to respond. Advent said it offered 58 euros per share, limited until Monday, and made its takeover conditional on receiving an endorsement from...

  • *Advent makes binding 58 euros/ share offer. FRANKFURT, Feb 23- Buyout firm Advent International raised the stakes in the three-way bidding tussle for German drug company Stada Arzneimittel on Thursday with a 3.6 billion euro takeover offer, giving management until Monday to respond. Previous expressions of interest, which have been non-binding, were 56 euros...

  • NEW YORK, Feb 23- A former Valeant Pharmaceuticals International Inc executive and the former chief executive of mail order pharmacy Philidor Rx Services pleaded not guilty on Thursday to charges they orchestrated a multi-million dollar fraud and kickback scheme. Federal prosecutors accused Gary Tanner, who was a senior director at Canadian drugmaker...

  • Could the border adjustment battle derail tax reform?

    CNBC's Ylan Mui discusses how the Trump administration's planned overhaul of the tax code could impact inversion deals and drug companies.

  • SHANGHAI, Feb 23- China has updated list of medicines covered by basic medical insurance schemes, a long-awaited fillip for drugmakers in the world's second-largest drug market where many new drugs have been kept out of patients' reach because of high costs. High drug costs and a lack of access to the most recent treatments is a major flashpoint in China, where...

  • COPENHAGEN, Feb 22- Danish biotech drugmaker Genmab's Darzalex, which is used to fight cancer in bone marrow and marketed by Johnson& Johnson, has the potential to achieve annual peak annual sales as high as $13 billion, its chief executive told Reuters. So that means $13 billion potential if it would work in all the indications, Jan van de Winkel said on Wednesday.

  • BMY clearly 'attractive' takeover target: Pro

    Barbara Ryan, Barbara Ryan Advisors, talks about Carl Icahn's stake in Bristol-Myers and other possible big pharma deals in 2017.

  • Activist Carl Icahn pressures Bristol-Myers

    CNBC's Meg Tirrell reports billionaire investor Carl Icahn takes a stake in Bristol-Myers Squibb and could see it as a possible takeover target.

  • Pharma business is doing very well: Bayer CEO

    Bayer CEO Werner Baumann talks about diversification in the company, with specific comment on its pharmaceutical business.

  • Brian McGee, strategy consultant at Novasecta, takes a look at Bayer's recent earnings while commenting on the firm’s outlook as it continues working with Monsanto.

  • Traders work on the main trading floor of the New York Stock Exchange as the Dow Jones industrial average passes the 20,000 mark shortly after the opening of the trading session on Jan. 25, 2017.

    These are the stocks posting the largest moves after the bell.

  • Feb 21- Billionaire investor Carl Icahn has taken a stake in Bristol-Myers Squibb Co and sees the drugmaker as a possible takeover target, according to a report published on Tuesday that sent the company's shares from a loss to more than 2 percent higher. Earlier on Tuesday, Bristol-Myers said it added three directors to its board, a move supported by JANA...